For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.
Menu
Reconstitution calculator

Peptide research reference

Semaglutide + Cagrilintide (CagriSema) Stack: Components & Protocol Reference

Evidence grade Human clinical trialBy Sam, MBALast reviewed October 2026

Each compound in Semaglutide + Cagrilintide (CagriSema) is its own vial, with its own reconstitution and cited dose ranges. A combined schedule appears only when a source publishes one.

Components of Semaglutide + Cagrilintide (CagriSema)

Each compound is a separate vial with its own reconstitution and its own cited dose ranges.

Source for this combination[1] Human clinical trial

Once-weekly co-administration of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist). In the 68-week phase 3a REDEFINE 1 trial in adults with overweight or obesity, cagrilintide 2.4 mg plus semaglutide 2.4 mg gave a mean 20.4% reduction in body weight versus 3.0% with placebo.

Vials in this stack: 2, one per component. The cycle calculator works out the number of vials and the cost of a cycle for each component.

Label figures describe the approved branded products. The research materials listed on this page are not approved drugs and are not evaluated by any regulator.

Vial 1: Semaglutide

Cited dose ranges

Semaglutide: Cited dose ranges
SourcePopulationDoseFrequencyEvidence
Ozempic US label (DailyMed)[2]humanadults with type 2 diabetes mellitus (labelled indications)0.25–2 mg[2]subcutaneous, starting dose (initiation); label heading "Recommended Initiation Dosage": 0.25 mg once weekly for 4 weeks, then increasedonce weekly Approved product label
Wegovy injection US label (DailyMed)[3]humanadults and pediatric patients aged 12 years and older with obesity, and adults with overweight plus a weight-related condition (labelled indications for the injection)0.25–7.2 mg[3]subcutaneous, starting dose (initiation); label heading "Recommended Starting Dosage": 0.25 mg once weekly for weeks 1-4, then escalatedonce weekly Approved product label

Vial 2: Cagrilintide

Cited dose ranges

Cagrilintide: Cited dose ranges
SourcePopulationDoseFrequencyEvidence
Phase 2 dose-finding trial (Lancet 2021, doi 10.1016/S0140-6736(21)01751-7; NCT03856047; 706 adults assigned to cagrilintide)[4]humanadults without diabetes with BMI 30 or higher, or 27 or higher with hypertension or dyslipidaemia, phase 2 trial0.3–4.5 mg[4]subcutaneous, trial dose arms 0.3, 0.6, 1.2, 2.4 and 4.5 mg once weekly; 0.3 mg is the lowest armonce weekly Human clinical trialStudy details from the source: Phase 2 dose-finding trial (Lancet 2021, doi 10.1016/S0140-6736(21)01751-7; NCT03856047; 706 adults assigned to cagrilintide): subcutaneous self-injection once weekly at 0.3, 0.6, 1.2, 2.4 or 4.5 mg for 26 weeks including a dose-escalation period of up to 6 weeks, versus liraglutide 3.0 mg once daily or placebo

Combined schedule

A schedule for the combination, as published in the cited source.

Cagrilintide 2.4 mg plus semaglutide 2.4 mg, each once weekly, for 68 weeks (the REDEFINE 1 maintenance dose).[1] Human clinical trial

Source for the schedule

Supplies checklist

What to have ready before you reconstitute.

  • Bacteriostatic water (BAC water), USPUSP bacteriostatic water contains benzyl alcohol and is labelled only as a diluent; CDC: date a multiple-use vial and discard it within 28 days. Source: labeling.pfizer.com
  • U-100 insulin syringe, 1 mL (100 units)Standard U-100 insulin syringes hold 1 mL (100 units); each small notch on a 1 mL syringe is 1 unit. Source: medlineplus.gov
  • Alcohol prep pads (isopropyl)CDC lists alcohol wipes among supplies for the medication preparation area; MedlinePlus: wipe the vial top with an alcohol wipe. Source: cdc.gov
  • FDA-cleared sharps disposal containerFDA recommends used needles and sharps go immediately into an FDA-cleared sharps disposal container, made of rigid plastic with a fill line. Source: fda.gov

All supplies and why each is needed

Frequently asked questions

Which compounds are in Semaglutide + Cagrilintide (CagriSema)?

The stack is documented as the combination of Semaglutide, Cagrilintide, each in its own vial [1].

Is a combined schedule published for Semaglutide + Cagrilintide (CagriSema)?

The cited schedule is: Cagrilintide 2.4 mg plus semaglutide 2.4 mg, each once weekly, for 68 weeks (the REDEFINE 1 maintenance dose). [1] (Human clinical trial).

References

Numbered sources used on this page. Markers in the text link here.

  1. pubmed.ncbi.nlm.nih.gov Human trial
  2. Ozempic US label (DailyMed) dailymed.nlm.nih.gov Approved label
  3. Wegovy injection US label (DailyMed) dailymed.nlm.nih.gov Approved label
  4. Phase 2 dose-finding trial (Lancet 2021, doi 10.1016/S0140-6736(21)01751-7; NCT03856047; 706 adults assigned to cagrilintide) pubmed.ncbi.nlm.nih.gov Human trial

Available from Pepcore

Supplied as research material for laboratory use only.

  • GLP-1(S) Research Material – 5mg 5 mg$59.99On backorder at Pepcore
    Shop at PepcoreCoupon code LAUNCH20
  • Cagrilintide Research Material – 10mg 10 mg$99.99
    Shop at PepcoreCoupon code LAUNCH20

Peptide Protocol Check may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.